



US009410938B2

(12) **United States Patent**
Comhair et al.

(10) **Patent No.:** **US 9,410,938 B2**
(45) **Date of Patent:** **Aug. 9, 2016**

(54) **BIOMARKERS FOR ASTHMA**

(71) Applicant: **The Cleveland Clinic Foundation,**
Cleveland, OH (US)

(72) Inventors: **Suzy Comhair,** Concord Township, OH
(US); **Satish Kalhan,** Pepper Pike, OH
(US); **Stanley Hazen,** Pepper Pike, OH
(US)

(73) Assignee: **THE CLEVELAND CLINIC**
FOUNDATION, Cleveland, OH (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/893,425**

(22) Filed: **May 14, 2013**

(65) **Prior Publication Data**

US 2013/0315898 A1 Nov. 28, 2013

Related U.S. Application Data

(60) Provisional application No. 61/646,609, filed on May
14, 2012.

(51) **Int. Cl.**

A61B 5/145 (2006.01)
A61K 31/40 (2006.01)
A61K 31/395 (2006.01)
A61K 47/18 (2006.01)
G01N 33/483 (2006.01)
G01N 33/49 (2006.01)
G01N 33/493 (2006.01)

(52) **U.S. Cl.**

CPC **G01N 33/483** (2013.01); **A61B 5/145**
(2013.01); **A61B 5/14546** (2013.01); **A61K**
31/395 (2013.01); **A61K 31/40** (2013.01);
A61K 47/183 (2013.01); **G01N 33/49**
(2013.01); **G01N 33/493** (2013.01)

(58) **Field of Classification Search**

None
See application file for complete search history.

(56) **References Cited**

PUBLICATIONS

Laidlaw et al. 'Plasma and urine taurine levels in vegans.' Am J Clin
Nutr 47:660-663, 1988.*
Trautwein et al. 'Taurine concentrations in plasma and whole blood
in humans: estimation of error from intra- and interindividual varia-
tion and sampling technique.' Am J. Clin Nutr 52:758-764, 1990.*

Ghandforoush-Sattari et al. 'Changes in plasma concentration of
taurine in stroke.' Neuro. Lett. 496:172-175, 2011.*
Blesa et al. 'Effectiveness of oral N-acetylcysteine in a rat experi-
mental model of asthma.' Pharm. Res. 45(2):135-140, 2002.*
Hofford et al. 'Levels of amino acids and related compounds in
bronchoalveolar lavage fluids of asthmatic patients.' Am. J. Respir.
Crit. care Med. 155:432-435, 1997.*
Trautwein et al. 'Taurine concentrations in plasma and whole blood
in humans: estimation of error from intra- and interindividual varia-
tion and sampling technique.' Am. J. Clin. Nutr 52:758-764, 1990.*
Lipworth et al. 'Leukotriene-receptor antagonists.' Lancet 353:57-62,
1999.*

Agackiran et al., "The efficiency of proanthocyanidin in an experi-
mental pulmonary fibrosis model: comparison with taurine," *Inflam-
mation*. Aug. 2012;35(4):1402-10. doi: 10.1007/s10753-012-9453-
6.

Cortijo et al., "Effects of taurine on pulmonary responses to antigen
in sensitized Brown-Norway rats," *Eur J Pharmacol*, Nov. 9, 2001;
431(1):111-7.

Demincie et al., "Taurine supplementation does not decrease
homocysteine levels and liver injury induced by a choline-deficient
diet," *Life Sci*. Apr. 23, 2014. pii: S0024-3205(14)00426-3. doi:
10.1016/j.lfs.2014.04.015. [Epub ahead of print].

Guler et al., "Taurine attenuates lung ischemia-reperfusion injury
after lung transplantation in rats," *J Anesth.*, Nov. 6, 2013. [Epub
ahead of print].

Gurujeyalakshmi et al., "Taurine and niacin block lung injury and
fibrosis by down-regulating bleomycin-induced activation of tran-
scription nuclear factor-kappaB in mice," *J Pharmacol Exp Ther.*,
2000, 293(1):82-90.

Wenting et al., "Therapeutic effect of taurine against aluminum-
induced impairment on learning, memory and brain neurotransmit-
ters in rats," *Neurol Sci.*, 2014, [Epub ahead of print].

Zr et al., "Effects of taurine on the expression of nitric oxide synthase
in lung of rats exposed to silica," *Zhonghua Lao Dong Wei Sheng Zhi*
Ye Bing Za Zhi, 2005, 23(2):116-8.

* cited by examiner

Primary Examiner — Nora Rooney

(74) *Attorney, Agent, or Firm* — Casimir Jones, S.C.; Jason
R. Bond

(57) **ABSTRACT**

The present invention provides methods, kits, and composi-
tions related to testing a sample for the level of a biomarker
related to asthma, wherein the biomarker is selected from:
taurine, maltose, maltotriose, adenosine 5'-monophosphate,
phosphoethanolamine, glycerophosphorylcholine, arachido-
nate, heptanoate, pelargonate, and nicotinamide. In certain
embodiments, the level of the biomarker is used to identify
therapy effective for treating asthma. In other embodiments,
the level of the biomarker is used to identify the presence,
severity, or risk of exacerbation of asthma. In further embodi-
ments, the level of the biomarker is used to monitor the
response to on-going therapy (e.g., adjust the dosage of the
asthma therapy).

3 Claims, 8 Drawing Sheets